MX2017014586A - Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio. - Google Patents
Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio.Info
- Publication number
- MX2017014586A MX2017014586A MX2017014586A MX2017014586A MX2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A MX 2017014586 A MX2017014586 A MX 2017014586A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- polyethylene glycol
- protein solution
- methoxy polyethylene
- site
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 150000001412 amines Chemical class 0.000 title 1
- 230000006320 pegylation Effects 0.000 title 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 6
- 229920001223 polyethylene glycol Polymers 0.000 abstract 5
- 239000012460 protein solution Substances 0.000 abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 229960000958 deferoxamine Drugs 0.000 abstract 2
- 239000006174 pH buffer Substances 0.000 abstract 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 abstract 2
- DRAJWRKLRBNJRQ-UHFFFAOYSA-N Hydroxycarbamic acid Chemical compound ONC(O)=O DRAJWRKLRBNJRQ-UHFFFAOYSA-N 0.000 abstract 1
- 108010049175 N-substituted Glycines Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los ejemplos incluyen un método para hacer un conjugado de proteínas PEGiladas. El método puede incluir proporcionar una solución acuosa de proteínas. La solución acuosa de proteínas puede incluir una proteína, un amortiguador de pH, y un agente quelante. El agente quelante puede elegirse del grupo que consta de un ácido aminopolicarboxílico, un ácido hidroxiaminocarboxílico , una glicina N-sustituida, ácido 2-(2-amino-2-oxoctil) aminoetano sulfónico (BES), y deferoxamina (DEF). El método también puede incluir la introducción de un cianoborohidruro de sodio y un metoxipolietilenglicol aldehído a la solución acuosa de proteínas. El cianoborohidruro de sodio en el metoxipolietilenglicol aldehído puede tener una relación molar que se encuentra en el rango de entre 5:1 a alrededor de 1.5:1. El método puede incluir además la reacción del metoxipolietilenglicol aldehído con la proteína para formar el conjugado de proteínas PEGiladas. El amortiguador de pH puede mantener un pH de la solución acuosa de proteínas que se encuentra en el rango de 4.0 a 4.4 durante la reacción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170933P | 2015-06-04 | 2015-06-04 | |
| PCT/US2016/033190 WO2016196017A1 (en) | 2015-06-04 | 2016-05-19 | Amine pegylation methods for the preparation of site-specific protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014586A true MX2017014586A (es) | 2018-03-09 |
Family
ID=57442063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014586A MX2017014586A (es) | 2015-06-04 | 2016-05-19 | Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10220075B2 (es) |
| EP (1) | EP3302450A4 (es) |
| JP (1) | JP2018516874A (es) |
| KR (1) | KR20180015131A (es) |
| CN (1) | CN107708679A (es) |
| AU (1) | AU2016270302B2 (es) |
| BR (1) | BR112017023145A2 (es) |
| CA (1) | CA2981501A1 (es) |
| MX (1) | MX2017014586A (es) |
| RU (1) | RU2730848C2 (es) |
| WO (1) | WO2016196017A1 (es) |
| ZA (1) | ZA201708573B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115029204A (zh) * | 2022-07-15 | 2022-09-09 | 曾会明 | 一种具有sod活性的酒及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
| US6323311B1 (en) * | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| US20050277586A1 (en) | 2002-04-11 | 2005-12-15 | Yasushi Taguchi | Peptide chemically modified with polyethylene glycol |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| DE60313786T2 (de) | 2002-09-27 | 2008-01-24 | F. Hoffmann-La Roche Ag | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 |
| WO2004063250A1 (en) | 2003-01-06 | 2004-07-29 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polmer derivatives |
| SI1605897T1 (sl) | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
| EP1613272B1 (en) * | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| WO2005061701A1 (ja) | 2003-12-24 | 2005-07-07 | Shionogi & Co., Ltd. | タンパク質のポリマー複合体の製造方法 |
| AU2004311796A1 (en) | 2003-12-31 | 2005-07-21 | Centocor, Inc. | Novel recombinant proteins with N-terminal free thiol |
| KR20060029770A (ko) | 2004-10-04 | 2006-04-07 | 주식회사 펙스피어 | Ｇｌｐ－１의 선택적 ｐｅｇ 접합체 및 그 제조방법 |
| EP1881850B1 (en) | 2005-05-13 | 2010-09-29 | Eli Lilly And Company | Glp-1 pegylated compounds |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| RU2424246C2 (ru) | 2006-05-26 | 2011-07-20 | Ипсен Фарма С.А.С. | Способы сайт-специфического пегилирования |
| CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| JP2008156283A (ja) * | 2006-12-25 | 2008-07-10 | Kyowa Hakko Kogyo Co Ltd | 水溶性ポリマー修飾ポリペプチドの製造方法 |
| EP2344200A2 (en) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| CA2775287A1 (en) | 2009-09-25 | 2011-03-31 | Vybion, Inc. | Polypeptide modification |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| WO2012054882A1 (en) | 2010-10-21 | 2012-04-26 | Kci Licensing, Inc. | Debridement hand tool |
| WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
| KR101746686B1 (ko) | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
| US9133188B2 (en) * | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
| CN102786590A (zh) | 2011-05-19 | 2012-11-21 | 江苏豪森药业股份有限公司 | 分枝型peg修饰的glp-1类似物及其可药用盐 |
| EP3808378A1 (en) | 2011-05-27 | 2021-04-21 | Baxalta GmbH | Therapeutic proteins with increased half-life and methods of preparing same |
| RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
| AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| CA2933701C (en) | 2013-12-18 | 2022-05-31 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
-
2016
- 2016-05-19 WO PCT/US2016/033190 patent/WO2016196017A1/en active Application Filing
- 2016-05-19 AU AU2016270302A patent/AU2016270302B2/en not_active Expired - Fee Related
- 2016-05-19 KR KR1020177033595A patent/KR20180015131A/ko unknown
- 2016-05-19 US US15/158,898 patent/US10220075B2/en not_active Expired - Fee Related
- 2016-05-19 JP JP2017555782A patent/JP2018516874A/ja not_active Ceased
- 2016-05-19 BR BR112017023145A patent/BR112017023145A2/pt not_active Application Discontinuation
- 2016-05-19 MX MX2017014586A patent/MX2017014586A/es unknown
- 2016-05-19 RU RU2017145825A patent/RU2730848C2/ru active
- 2016-05-19 CN CN201680030022.XA patent/CN107708679A/zh active Pending
- 2016-05-19 EP EP16803982.4A patent/EP3302450A4/en not_active Withdrawn
- 2016-05-19 CA CA2981501A patent/CA2981501A1/en not_active Abandoned
-
2017
- 2017-12-15 ZA ZA2017/08573A patent/ZA201708573B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107708679A (zh) | 2018-02-16 |
| AU2016270302A1 (en) | 2017-10-19 |
| US20160354478A1 (en) | 2016-12-08 |
| ZA201708573B (en) | 2019-08-28 |
| BR112017023145A2 (pt) | 2018-07-10 |
| RU2017145825A3 (es) | 2019-11-18 |
| WO2016196017A1 (en) | 2016-12-08 |
| AU2016270302B2 (en) | 2020-09-17 |
| KR20180015131A (ko) | 2018-02-12 |
| EP3302450A1 (en) | 2018-04-11 |
| JP2018516874A (ja) | 2018-06-28 |
| CA2981501A1 (en) | 2016-12-08 |
| EP3302450A4 (en) | 2019-01-16 |
| RU2730848C2 (ru) | 2020-08-26 |
| RU2017145825A (ru) | 2019-07-10 |
| US10220075B2 (en) | 2019-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190878T1 (hr) | Modificirane aminokiseline koje sadrže azidnu grupu | |
| MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
| MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
| MX2019001253A (es) | Conjugados de proteina-agente activo y metodo para su preparacion. | |
| BR112013031028A2 (pt) | conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles | |
| NI201700076A (es) | Complejos radiofarmacéuticos | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| EA201391402A1 (ru) | Буферная система для очистки белка | |
| MX2017006594A (es) | Proteinas y congujados proteinicos con efecto hidrofobo aumentado. | |
| MX2015012527A (es) | Polipeptidos de union hiperglicosilados. | |
| EA201592055A1 (ru) | 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов | |
| MX2013011259A (es) | Proceso de aminacion reductora para la preparacion de la dronedarona usando el compuesto intermediario de amina. | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| MX2012003296A (es) | Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina. | |
| MY156211A (en) | Method for preparation of an aqueous glyphosate concentrate composition having mixture of amine salts | |
| MX2014007125A (es) | Uso de n-hidroxisuccinimida para mejorar la estabilidad de conjugados. | |
| BRPI0807054A8 (pt) | Mistura de sais, composição aquosa, e, método de preparação da composição | |
| MX2022005884A (es) | Tecnologías de conjugación dirigida. | |
| BR112015023233A2 (pt) | conjugados de hemoglobina, composição farmacêutica e métodos de tratamento | |
| MX2017014586A (es) | Pegilacion de aminas para la preparacion de conjugados de proteinas especificos de un sitio. | |
| AR094987A1 (es) | Proceso mejorado para la preparación a alto rendimiento de un complejo polipeptídico fisiológicamente activo | |
| MX2020012350A (es) | Anticuerpos anti-cd63, conjugados y usos de estos. | |
| CY1115161T1 (el) | Διαδικασια για την παραγωγη 2-[(3,5-διφθορο-3'-μεθοξυ-1,1'-διφαινυλ-4-υλ)αμινο]νικοτινικου οξεος | |
| NZ599861A (en) | Improved process for preparing soluble granules of salts of pyridine containing carboxylic acids | |
| PH12020552282A1 (en) | Improvements in immunogenic conjugates |